Dolutegravir Improves Long-Term HIV Outcomes in Children and Adolescents
|
Among children and adolescents living with HIV,
dolutegravir (DTG)-based antiretroviral therapy (ART) demonstrates
sustained superior efficacy ... |
Misinformation threatens rollout of HIV prevention drug lenacapavir
Health experts say false claims about the lenacapavir injection could undermine efforts to reduce new HIV infections in South Africa. View article...